The National Health Insurance Directory adjusts the depth of the eight charts.

On September 18, the official website of the State Health Insurance Administration published the List of Declared Drugs for the 2020 National Health Insurance Drug Catalog Adjustment through Formal Review, and substantial progress has been made in the health care negotiations in 2020.
this paper will be combined with the first four national health insurance drug negotiations, the current medical insurance negotiations analysis and prejudgment.
1, the number of varieties: a total of 751 varieties passed the formal review, in addition to 23 need to adjust the payment price and adaptation, functional treatment and other changes of the original negotiating varieties, the new 728, of which 551 Western medicine, 177 Chinese medicine, is the most in the past, in 2019, a total of 70 new varieties of successful negotiations, including 52 Western medicine, Chinese medicine 18.
II, involving: very wide this national talk variety is not only a large number, but also a very wide range, which meets the "December 31, 2019, into more than 5 (including) provincial version of the latest version of basic medical insurance drugs" requirements of the largest number of drugs, reached 493 drugs, accounting for Two-thirds of the total, followed by 171 new generic drugs and adaptive drugs and functional treatments approved by the State Drug Administration between January 1, 2015 and August 17, 2020, accounting for a quarter.
3, success rate: will not be too high the number of varieties, how many successful selection is not yet known, however, before, the relevant leadership of the Health Insurance Bureau has predicted that the success rate will not be too high, indeed, this only previously in the local health insurance catalog of old drugs accounted for 2/3, up to 493, may not be as high as the success rate of the new batch of listed varieties.
4, the price reduction range: will not be too low preliminary estimate of this price reduction will not be low, because in the four rounds of national volume procurement has been carried out in the atmosphere of substantial price reduction, 493 old varieties of price reduction will be the first to suffer.
5, PDx: all debut as leading domestic pharmaceutical innovation PDx (PD-1, PDL-1), last year's national talks have attracted much attention, the result is only Thyda's Xindili was selected, and its decline is also very sincere, into health insurance, 60KG weight patients from the previous 270,000 yuan / year down to 967,000 yuan, 12 times lower than the burden of K medicine in the United States.
year, there are a lot of PDx listed, and their respective after-sales performance is also very good (Figure 6), I believe that PDx's national talks will be more intense.
6. Orphan medicine: will not be absent since the previous year China introduced a classification system and series of incentives for rare diseases, rare disease drugs (orphan drugs) development in full swing, last year there were a number of orphan drugs negotiations successfully, this year another 18 passed the formal review, it is estimated that this year more orphan drugs will be successfully entered into health insurance.
in China is still in its infancy, but in Europe, the United States and Japan and other developed countries have become large-scale (Figure 7).
7. Inhalants: high-profile appearance due to the volume of procurement of generic drugs to reduce the price of large, innovative drugs time-consuming and expensive, recently, the domestic set off a wave of research and development of modified preparations, the Drug Enforcement Administration has also issued relevant regulations, this time 11 inhalers passed the review, is expected to have a number of successful negotiations.
, inhalers in the domestic market already have a considerable market size, and has been born a number of star varieties.
according to the work schedule, the 2020 NATIONAL Health Care Directory adjustment will also go through the expert review phase (September-October 2020) negotiation and bidding phase (October-November 2020), with the results to be announced by the end of the year.
what the final outcome will be, let's wait and see.
.